SSG
CCXI

Summit Securities Group’s ChemoCentryx, Inc. CCXI Stock Holding History

Summit Securities Group’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-300
Closed -$4K – 582
2013
Q2 		$4K Buy
+300
New +$3.89K ﹤0.01% 427

Other funds holding CCXI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Summit Securities Group's CCXI Position: Q3 2013 in Review

Summit Securities Group sold out of ChemoCentryx, Inc. (CCXI) in Q3 2013, closing a stake of 300 shares — an estimated $4K sold.

Summit Securities Group first reported a position in CCXI in Q2 2013 and held it in 1 quarter. The position peaked at $4K in Q2 2013. 66 funds tracked by Wall St. Rank hold CCXI as of Q3 2013.

  • Summit Securities Group reported no remaining ChemoCentryx, Inc. position as of Q3 2013 after selling out during the quarter.
  • Summit Securities Group sold 300 ChemoCentryx, Inc. shares in Q3 2013, an estimated $4K.
  • Summit Securities Group first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 1 quarter.
  • Summit Securities Group's ChemoCentryx, Inc. position peaked at $4K in Q2 2013.
  • 66 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2013.

Based on Summit Securities Group's 13F filing for Q3 2013, filed 1 Nov 2013.